ERBB2 and cancer: While HER-2 blockade has had a transformative impact on this cancer subtype, the advent of CDK-cyclin inhibitors (iCDK) in the luminal subtype has also significantly improved survival in patients with hormone receptor-positive breast cancer [17–19].